
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health has reported a two-year revenue compound annual growth rate (CAGR) increase of 28% for the period from 2023 to 2025, driven by anticipated strength in colorectal cancer (CRC), breast cancer, and other indicators, along with new monitoring applications and product upgrades. The company has exceeded revenue estimates from its new test, Shield, and raised its annual revenue guidance for the test, anticipating approximately 31% year-over-year growth for 2025. Furthermore, the introduction of Reveal as the fastest-growing oncology test and improvements in reimbursement coverage for breast cancer testing are expected to enhance average selling prices (ASPs) and bolster overall volumes, positioning Guardant Health favorably within the market.
Bears say
Guardant Health's medium-term revenue guidance for its Shield product was perceived as underwhelming, contributing to concerns about future earnings potential. The company's adjusted EBITDA loss of $45.5 million in the third quarter of 2025 raises questions about its financial health and sustainability, particularly in the context of ongoing high research and development expenditures. Additionally, uncertainties surrounding regulatory approvals, reimbursement processes, and potential delays in product launches could further destabilize the company's stock performance.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares